Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6413
    -0.0012 (-0.19%)
     

  • OIL

    82.43
    -0.30 (-0.36%)
     

  • GOLD

    2,394.90
    -3.10 (-0.13%)
     

  • Bitcoin AUD

    101,119.00
    +5,169.88 (+5.39%)
     

  • CMC Crypto 200

    1,335.67
    +23.05 (+1.79%)
     

  • AUD/EUR

    0.6018
    -0.0013 (-0.21%)
     

  • AUD/NZD

    1.0893
    +0.0018 (+0.17%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,828.70
    -48.35 (-0.61%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,712.52
    -124.88 (-0.70%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Molecular Templates to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Molecular Templates, Inc.
·1-min read

AUSTIN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, will present and participate in 1-on-1 investor meetings at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, to take place September 20-23, 2021.

Presentation details can be found below:

Presenter:

Dr. Eric Poma, CEO and CSO

Date:

Monday, September 20th

Time:

4:35 PM ET

Webcast:

https://wsw.com/webcast/oppenheimer16/mtem/2788953

About Molecular Templates
Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.

Investor Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Molecular Templates, Inc.